Which test includes MSI and TMB metrics for profiling tumors?

• A. Precise Tumor
• B. MyChoice CDx
• C. BRACAnalysis
• D. Oncoplex

Answer: (A)

Tumor profiling that reports both microsatellite instability (MSI) and tumor mutational burden (TMB) helps identify tumors likely to respond to immunotherapy, since MSI-H reflects mismatch repair deficiency and high TMB indicates a higher number of neoantigens. Among common profiling panels, the test that provides both MSI status and a TMB calculation is Oncoplex, making it the best fit for profiling tumors with these two metrics. The other options are more focused on different aspects: BRACAnalysis assesses germline BRCA mutations, MyChoice CDx centers on homologous recombination deficiency related to BRCA pathways, and Precise Tumor isn’t typically recognized for routinely delivering both MSI and TMB.